Jonas Bergh holds the Mimi Althainz’ Professorship in Oncology at Karolinska Institutet (KI) and is senior consultant Radiumhemmet, Karolinska University Hospital in Stockholm, Sweden. He has recently been appointed Director for the Strategic Research Program in Cancer at KI. Between 2009 and 2010, he was Professor of Breast Oncology at Manchester University in England. Professor Bergh's research is mainly focused on tailored breast cancer treatment.
Jonas Bergh was Chair of the Swedish Breast Cancer Group between 1995 and 2016. During this period he conducted clinical trials with new drugs and individually tailored dosing of chemotherapy. Through this group, he also participated in the first randomised study showing that five years of tamoxifen treatment is better that the previously recommended two years. He has been involved in showing the additional value of other drugs, in particular chemotherapy, in breast cancer treatment.
Bergh has an extensive scientific publication within the field of discovery and validation of tumour biomarkers. He is author of some 400 publications, manuscripts and varia. He has participated in several editorial boards for scientific journals as well as acting as an external expert consultant for the Swedish Medical Products Agency.
Bergh is currently acting Chair of the Scientific Advisory Group Oncology-Hematology at the European Medicines Agency (EMA), where he has been member since 2004. He is co-chairman for a global network, Early Breast Cancer Trialists’ Collaborative Group, with over 600 clinical scientists. The group’s publications have a globally great impact on primary breast cancer treatment. Bergh is also a member of the consensus panels establishing treatment recommendations for primary and metastatic breast cancer; also of great importance for breast cancer treatment in many countries.
Jonas Bergh is also fellow in Royal College of Physicians in London, member of the scientific council IARC for WHO, Visiting Professor of Breast Cancer Research, Oxford University and member of the Nobel Assembly.